# Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

> **NCT06375044** · PHASE1 · RECRUITING · sponsor: **Jiangsu Simcere Pharmaceutical Co., Ltd.** · enrollment: 130 (estimated)

## Conditions studied

- Relapsed or Refractory Multiple Myeloma

## Interventions

- **DRUG:** SIM0500

## Key facts

- **NCT ID:** NCT06375044
- **Lead sponsor:** Jiangsu Simcere Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-24
- **Primary completion:** 2026-06-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2026-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06375044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06375044, "Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06375044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*